.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Fibrocell Science, Inc. Enters Into Financing Agreement
EXTON, Pa., March 2 /PRNewswire-FirstCall/ -- Fibrocell Science, Inc. (OTCBB:FCSC.ob - News) announced today that the Company has entered into a Securities Purchase Agreement with certain accredited investors, pursuant to which the Company agreed to sell to the purchasers in the aggregate 5,076,667 shares of Company common stock at a purchase price of $0.75 per share. Each purchaser will also receive a warrant to purchase the same number of shares of common stock acquired in the offering at an exercise price of $0.98 per share. The aggregate purchase price to be paid by the purchasers at closing for the common stock and the warrants will be $3,807,500. The financing is subject to customary closing conditions. None of the shares to be issued to the investors nor the shares underlying the warrants to be issued to the investors or the placement agents will be or have been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
Viriathus Capital LLC and John Carris Investments LLC were co-placement agents for the transaction.
About Fibrocell Science, Inc.
Fibrocell Science, Inc. (OTCBB:FCSC.ob - News) is a biotechnology company focused on the development of regenerative cell therapy for aesthetic, medical and scientific applications. Fibrocell Science is committed to advancing the scientific, medical and commercial potential of autologous skin and tissue, as well as its innovative cellular processing technology and manufacturing excellence. For additional information, please visit www.fibrocellscience.com.
Forward Looking Statements
All statements in this press release that are not based on historical fact are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of the Company’s control, that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under Item 1A “Risk Factors” in the Company's Annual Report on Form 10-K for the year ended December 31, 2008, as updated in “Item 1A. Risk Factors” in the Company's Quarterly Reports on Form 10-Q filed since the annual report. The Company operates in a highly competitive and rapidly changing environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. The Company disclaims any intention to, and undertakes no obligation to, update or revise any forward-looking statements. Readers are also urged to carefully review and consider the other various disclosures in the Company's public filings with the SEC.
Nabi shareholders approve deal with Glaxo
http://finance.yahoo.com/news/Nabi-shareholders-approve-apf-363631293.html?x=0&.v=1
Recent insider transactions: http://mffais.com/nabi
About Nabi Biopharmaceuticals, Inc.
Nabi Biopharmaceuticals, a biopharmaceutical company, develops products that address unmet medical needs in the areas of nicotine addiction and infectious disease in the United States. The company is developing NicVAX, a proprietary investigational vaccine for treatment of nicotine addiction and prevention of smoking relapse. It has a manufacturing services agreement with Biotest Pharmaceuticals Corporation, which enables it to obtain clinical lots of its retained products, as well as component products from Biotest. Nabi Biopharmaceuticals also has license and royalty agreements with National Institute of Allergy and Infectious Diseases; National Institute for Drug Abuse; Department of Defense; National Institutes of Health; and University of Maryland. The company was founded in 1967 and is headquartered in Rockville, Maryland.
Heska to Present at The Wall Street Analyst Forum's 21st Annual Analyst Conference
LOVELAND, Colo., March 2 /PRNewswire-FirstCall/ -- Heska Corporation (Nasdaq:HSKA - News) today announced it will present at The Wall Street Analyst Forum's 21st Annual Analyst Conference on Friday, March 12, 2010. The presentation will be at the University Club, 1 West 54th Street in New York City and is scheduled to begin at 2:20 p.m. Eastern Time (12:20 p.m. Mountain Time). The presentation will be available via live webcast and for two weeks following the presentation through a link on the investor relations portion of Heska Corporation's website.
(Logo: http://www.newscom.com/cgi-bin/prnh/20000622/HESKALOGO)
About Heska
Heska Corporation (NASDAQ:HSKA - News) sells advanced veterinary diagnostic and other specialty veterinary products. Heska's state-of-the-art offerings to its customers include diagnostic instruments and supplies as well as single use, point-of-care tests, pharmaceuticals and vaccines. The company's core focus is on the canine and feline markets where it strives to provide high value products and unparalleled customer support to veterinarians. For further information on Heska and its products, visit the company's website at www.heska.com.
Nabi Biopharmaceuticals' Stockholders Approve NicVAX Option and License Agreement
ROCKVILLE, Md., March 2, 2010 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI - News) (the "Company") announced that, at today's Special Meeting of Stockholders, its stockholders voted overwhelmingly to approve the exclusive option and license agreement for NicVAX(R) (Nicotine Conjugate Vaccine) with GlaxoSmithKline Biologicals S.A., dated as of November 13, 2009, and the transactions contemplated thereby.
More than 73 percent of the outstanding shares of the Company's common stock were voted in favor of the transaction. Of the shares that were voted, more than 99% were voted in favor of the transaction.
"We are pleased and gratified by the strong support we have received from our stockholders," said Dr. Raafat Fahim, President and Chief Executive Officer of Nabi Biopharmaceuticals. "We thank them for their approval of this agreement."
The Company expects to successfully meet the remaining closing requirements under the exclusive option and license agreement, including a mutual agreement between Nabi and GSK on an initial NicVAX development plan, and close the agreement by the end of the first quarter.
About Nabi Biopharmaceuticals
Nabi Biopharmaceuticals leverages its experience and knowledge in powering the immune system to develop products that target serious medical conditions in the areas of nicotine addiction and gram-positive bacterial infections. Nabi Biopharmaceuticals is currently developing NicVAX(R) (Nicotine Conjugate Vaccine), an innovative and proprietary investigational vaccine for treatment of nicotine addiction and prevention of smoking relapse. The company is headquartered in Rockville, Maryland. For additional information about Nabi Biopharmaceuticals, please visit www.nabi.com.
Forward-Looking Statements
Statements in this release that are not strictly historical are forward-looking statements and include statements about products in development, results and analyses of clinical trials and studies, research and development expenses, cash expenditures, licensure applications and approvals, and alliances and partnerships, among other matters. You can identify these forward-looking statements because they involve our expectations, intentions, beliefs, plans, projections, anticipations, or other characterizations of future events or circumstances. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements as a result of any number of factors. These factors include, but are not limited to, risks relating to our ability to: complete the remaining PentaStaph sale milestones; initiate and conduct clinical trials and studies; raise sufficient new capital resources to fully develop and commercialize our products in development; attract, retain and motivate key employees; collect further milestone and royalty payments under the PhosLo Agreement; obtain regulatory approval for our products in the U.S. or other markets; successfully contract with third party manufacturers for the manufacture and supply of NicVAX; consummate the closing under the NicVAX exclusive option and license agreement and complete the NicVAX regulatory, development and sales milestones thereunder; and comply with reporting and payment obligations under government rebate and pricing programs. Some of these factors are more fully discussed, as are other factors, in our Annual Report on Form 10-K for the fiscal year ended December 27, 2008 filed with the Securities and Exchange Commission.
May make new day high soon, level 2 looks thin.
GLTA.
Still under old symbol, but relevant: http://www.mffais.com/olgc
Trial data from AZX100 are expected to be released in 4Q2010.
GLTA.
About Capstone Therapeutics:
OrthoLogic Corp., doing business as Capstone Therapeutics, focuses on the development and commercialization of therapeutic peptides and other molecules for patients with under-served conditions. The company?s product includes Chrysalin, or TP508, a 23-amino acid synthetic peptide, which is under pre-clinical testing for vascular applications, such as acute myocardial infarction and chronic myocardial ischemia. It also offers AZX100, a synthetic 24-amino acid peptide to relax smooth muscle, which modulates blood pressure and the function of blood vessels, airways, sphincters, the gastrointestinal tract, and the genitourinary tract. AZX100 is also evaluated for medical and commercial applications, such as treatment of pulmonary disease, prevention of hypertrophic and keloid scarring, and intimal hyperplasia. The company was formerly known as IatroMed, Inc. and changed its name to OrthoLogic Corp. in July 1991. OrthoLogic Corp. was founded in 1987 and is based in Tempe, Arizona.
Capstone Therapeutics Announces Continuation of AZX100 Phase 2 Clinical Trial in Keloid Scarring
TEMPE, Ariz., March 2, 2010 (GLOBE NEWSWIRE) -- Capstone Therapeutics (Nasdaq:CAPS - News) announced today it has completed a limited analysis of a subset of data from one of its two ongoing AZX100 Phase 2a clinical trials in keloid scarring. The clinical trial will continue to its planned 12-month endpoints.
The company's goals for this analysis were to assess AZX100 ongoing safety, to evaluate the quality of the clinical trial dataset in order to guide future studies and to determine whether continuation of the trial would be futile from a statistical perspective.
"We have met our objectives for this preliminary analysis," said Randolph C. Steer, MD, PhD, President of Capstone Therapeutics. "Following a limited review by our independent statistician of the safety and quality of the dataset, we have been advised to continue the trial. The primary endpoint is the 12-month POSAS score; we expect to report data from this trial during 4Q2010."
The two ongoing AZX100 Phase 2 keloid clinical trials (OL-ASCAR-04, dosing 3.0mg and 10.0mg per linear cm - continuation announced today; and OL-ASCAR-05, dosing 0.3mg and 1.0mg per linear cm) are blinded, placebo-controlled, multicenter, parallel group dose ranging studies to evaluate the safety and preliminary efficacy of AZX100 following excision of keloid scars. The primary objective of the studies is to evaluate the efficacy of AZX100 based on the differences among dosage groups in Patient and Observer Scar Assessment Scale (POSAS) scores at 12 months. Secondary objectives include safety determination and evaluations of efficacy via validated scar assessment scales using both 2D and 3D digital photography. Fifty-nine subjects were dosed in each trial. The analysis reported today examined certain metrics from a subset of dosed subjects followed for six months post-excision.
About Capstone Therapeutics
Capstone Therapeutics (trade name of OrthoLogic Corp.) is a biotechnology company committed to developing a pipeline of novel therapeutic peptides aimed at helping patients with under-served medical conditions. The Company is focused on development and commercialization of two product platforms: AZX100 and Chrysalin(R) (rusalatide acetate or TP508).
AZX100 is a novel synthetic 24-amino acid peptide, one of a new class of compounds in the field of smooth muscle relaxation and fibrosis. Based on its demonstrated effects in pre-clinical models and safety in clinical trials, AZX100 is currently being evaluated for commercially significant medical applications such as the prevention or reduction of hypertrophic and keloid scarring, treatment of pulmonary disease and intimal hyperplasia. Capstone has an exclusive worldwide license to AZX100.
Chrysalin, the Company's novel synthetic 23-amino acid peptide, has been proven in multiple pre-clinical and clinical models to stimulate cellular events leading to angiogenesis, revascularization, and repair of dermal and musculoskeletal tissues. It is currently being evaluated in disorders that involve vascular endothelial dysfunction, such as acute myocardial infarction and chronic myocardial ischemia. The Company owns exclusive worldwide rights to Chrysalin.
Capstone's corporate headquarters are in Tempe, Arizona. For more information, please visit the Company's website: www.capstonethx.com.
The Capstone Therapeutics logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=5429
Statements in this press release or otherwise attributable to Capstone regarding our business that are not historical facts are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements, which include the timing and acceptability of FDA filings and the efficacy and marketability of potential products, involve risks and uncertainties that could cause actual results to differ materially from predicted results. These risks include: delays in obtaining or inability to obtain FDA, institutional review board or other regulatory approvals of pre-clinical or clinical testing; unfavorable outcomes in our pre-clinical and clinical testing; the development by others of competing technologies and therapeutics that may have greater efficacy or lower cost; delays in obtaining or inability to obtain FDA or other necessary regulatory approval of our products; our inability to successfully and cost effectively develop or outsource manufacturing and marketing of any products we are able to bring to market; changes in FDA or other regulations that affect our ability to obtain regulatory approval of our products, increase our manufacturing costs or limit our ability to market our product; effects on our stock price and liquidity if we are unable to meet the requirements for continued listing on the Nasdaq Capital Market; our need for additional capital in the future to fund the continued development of our product candidates; and other factors discussed in our Form 10-K for the fiscal year ended December 31, 2008, and other documents we file with the Securities and Exchange Commission.
Editor's Note: This press release is also available under the Investors section of the Company's website at www.capstonethx.com.
Dir AYLESWORTH Buys 18,000 Of HESKA CORP >HSKA
SOURCE: Form 4
ISSUER: HESKA CORP
SYMBOL: HSKA
FILER: AYLESWORTH WILLIAM A
TITLE: Director
DATE TRANSACTION SHARES PRICE VALUE
2/26/10 Purchase 18,000 $0.71 $12,712
OWNERSHIP: 80,000 (Direct)
The Form 4 is filed with the Securities and Exchange Commission by insiders
to report transactions in their companies' shares. Open market purchases
and sales must be reported within two business days of the transaction.
Insider Data Source: The Washington Service
(info@washingtonservice.com or 301-913-5100)
Click here to go to Dow Jones NewsPlus, a web front page of today's most
important business and market news, analysis and commentary:
http://www.djnewsplus.com/nae/al?rnd=aXDfCUdb1q9GLEHfSqdUXA%3D%3D. You can use
this link on the day this article is published and the following day.
(END) Dow Jones Newswires
03-02-10 1114ET
11:14 030210
Adamis Pharmaceuticals Announces Results and Adjournment of Special Meeting
SAN DIEGO, CA -- (Marketwire) -- 03/01/10 --
Adamis Pharmaceuticals Corporation (OTCBB: ADMP) announced today that its stockholders approved the previously announced proposed merger transaction with La Jolla Pharmaceutical Company at a special shareholders meeting held on Friday, February 26, 2010. Based on proxies received and voted at the meeting, holders of approximately 59% of the outstanding shares voted in favor of the merger transaction, and holders of less than 0.5% of the outstanding shares voted against the transaction.
Separately, La Jolla Pharmaceutical Company announced today in a press release that its special meeting of its stockholders convened on February 26, 2010 was adjourned to March 2, 2010, in order to permit La Jolla to solicit additional proxies from its stockholders in favor of the transaction and related proposals, and that as of the date of the meeting it had received proxies from holders of approximately 12% of its outstanding shares, and that the proxies received to date had overwhelmingly supported the merger proposals. The press release indicated that in order for the merger to be completed, holders of more than 50% of La Jolla's outstanding shares must vote in favor. The press release also indicated that if the common stock of La Jolla is delisted from NASDAQ before obtaining the necessary vote, La Jolla expects that it would need additional regulatory approvals to continue soliciting proxies, resulting in significant additional costs and time delays; and that such approvals are difficult to obtain and may not be obtained at all.
About Adamis Pharmaceuticals
Adamis Pharmaceuticals has two wholly owned subsidiaries, Adamis Laboratories and Adamis Viral Therapies. Adamis Labs expects to launch a series of niche prescription products in the allergy and respiratory therapeutic area, including its Epinephrine Injection USP 1:1000 (0.3mg Pre-Filled Single Dose Syringe) product launched last year. Adamis Viral Therapies is focused on the development of patented, proprietary technologies and recently entered into an agreement with Colby Pharmaceutical Company to acquire exclusive license agreements covering three small molecule compounds for the potential treatment of human prostate cancer. The completion of the acquisition is subject to satisfaction of certain closing conditions.
This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.
For Additional Information
Mark Bernhard Email Contact Mark Gundy Email Contact Capital Group Communications, Inc.
Tel: 415.332.7200
RxNews Recap for Monday 03-01-10. Ariad granted Orphan Drug status. Biodel up on NDA acceptance. Enzo soars on patent ruling.
http://biomedreports.com/articles/most-popular/30673-rxnews-recap-for-monday-03-01-10.html
ETF Update: Is Biotech the Future of Healthcare?
http://seekingalpha.com/article/191148-etf-update-is-biotech-the-future-of-healthcare
Delcath Systems Names Michael D. Dellario as Vice President, Global Marketing
NEW YORK, March 1 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq:DCTH - News), a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, announced today that it has named Michael D. Dellario, 57, to the newly-created position of Vice President, Global Marketing, effective today. Mr. Dellario will report to Agustin Gago, EVP, Global Sales and Marketing.
"The new position of Vice President, Global Marketing is a critical component as we build our domestic and international commercialization team in anticipation of FDA approval and CE designation for the Delcath PHP System™," said Mr. Gago. "Michael's record of success in bringing innovative medical products to worldwide markets gives us confidence that he will have a significant impact on the commercialization of the Delcath PHP System as we continue to implement our plans in key European and Asian markets."
Mr. Dellario was most recently a marketing consultant for startup medical companies in the early stages of marketing development, providing marketing strategies and commercialization support. Prior to that, Mr. Dellario was Managing Director, Asian Operations at E-Z-EM/Bracco Inc., a medical equipment and software, devices and diagnostic pharmaceuticals company, from 2006 to 2008. There, he designed a focused marketing program and channel distribution plan that grew Asian business by 78%. Before that, he was Vice President of Marketing at Ekos Corp., Inc., an interventional devices and equipment startup focusing on therapeutic ultrasound.
From 1992 to 2005, Mr. Dellario held several marketing positions at AngioDynamics, Inc. Prior to that, he held sales and marketing positions for medical technology companies. Mr. Dellario received his MBA from Lidenwood University and his BS from St. Louis University, both in St. Louis, Missouri.
About Delcath Systems, Inc.
Delcath Systems, Inc. is a medical technology company specializing in cancer treatment. The Company is testing a proprietary, patented drug delivery system for the treatment of primary and metastatic liver cancers. Delcath's novel drug delivery platform is testing the delivery of ultra-high doses of anti-cancer agents to the liver while controlling the systemic exposure of those agents. In addition to its fully enrolled Phase III metastatic melanoma study, the Company is currently conducting trials to treat other forms of tumor metastases to the liver. The Company maintains a broad intellectual property portfolio on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at www.delcath.com.
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.
La Jolla Pharmaceutical Company Announces the Adjournment of Special Meeting of Stockholders
SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (NASDAQ: LJPC - News) today announced that its Special Meeting of Stockholders, which was initially convened on February 26, 2010, was adjourned to March 2, 2010 at 3:00 p.m., local time, at 4365 Executive Drive, Suite 300, San Diego, California. As described in the joint proxy statement/prospectus distributed to stockholders on or about February 12, 2010, the stockholders of La Jolla are being asked to vote on proposals related to its proposed merger with Adamis Pharmaceuticals Corporation (OTCBB: ADMP - News).
Holders of only twelve percent (12%) of La Jolla’s outstanding common stock returned their proxy cards or otherwise indicated their votes with respect to these proposals prior to the start of the stockholders’ meeting. The votes cast as of the meeting date overwhelmingly supported the merger proposals, including the reverse stock split. Separately, Adamis announced today that its stockholders approved the proposed merger transaction.
There is no guarantee that we will be able to further adjourn and reconvene the meeting to solicit additional votes. If La Jolla is delisted from Nasdaq before the special stockholders’ meeting, La Jolla expects that it would need Adamis’ consent and additional regulatory approvals to continue soliciting proxies resulting in significant additional costs and time delays. Such consents and approvals are difficult to obtain and may not be obtained at all.
Holders of more than 50% of La Jolla’s 65 million shares outstanding must vote in order to hold the meeting. For the merger to be completed, holders of more than 50% of La Jolla’s shares must vote in favor. Only stockholders who held La Jolla stock on January 22, 2010 are eligible to vote.
If You Haven’t Received Your Voting Materials – please vote by contacting our proxy vote solicitor, Mackenzie Partners, Inc. as follows:
e-mail at proxy@mackenziepartners.com
call toll free at (800) 322-2885
call collect at (212) 929-5500.
Mackenzie Partners will be able to provide you with voting materials and instructions on how to vote telephonically or through your broker. You may also contact La Jolla by e-mail at gail.sloan@ljpc.com or by telephone at (858) 452-6600.
This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.
Additional Information and Where to Find It
The joint proxy statement/prospectus in connection with the merger with Adamis was mailed to La Jolla stockholders on or about February 12, 2010. Investors and security holders of both La Jolla and Adamis are urged to read the joint proxy statement/prospectus because it contains important information about La Jolla, Adamis and the proposed transaction. The joint proxy statement/prospectus, and any other documents filed by La Jolla with the SEC, may be obtained free of charge at the SEC web site at www.sec.gov, by contacting La Jolla Investor Relations by e-mail at gail.sloan@ljpc.com or by telephone at (858) 452-6600. La Jolla and its respective directors and executive officers may be deemed to be participants in the solicitation of proxies from La Jolla’s stockholders in favor of the proposed transaction. Information about the directors and executive officers of La Jolla and their respective interests in the proposed transaction is available in the joint proxy statement/prospectus.
La Jolla Pharmaceutical Company Announces the Adjournment of Special Meeting of Stockholders
SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (NASDAQ: LJPC - News) today announced that its Special Meeting of Stockholders, which was initially convened on February 26, 2010, was adjourned to March 2, 2010 at 3:00 p.m., local time, at 4365 Executive Drive, Suite 300, San Diego, California. As described in the joint proxy statement/prospectus distributed to stockholders on or about February 12, 2010, the stockholders of La Jolla are being asked to vote on proposals related to its proposed merger with Adamis Pharmaceuticals Corporation (OTCBB: ADMP - News).
Holders of only twelve percent (12%) of La Jolla’s outstanding common stock returned their proxy cards or otherwise indicated their votes with respect to these proposals prior to the start of the stockholders’ meeting. The votes cast as of the meeting date overwhelmingly supported the merger proposals, including the reverse stock split. Separately, Adamis announced today that its stockholders approved the proposed merger transaction.
There is no guarantee that we will be able to further adjourn and reconvene the meeting to solicit additional votes. If La Jolla is delisted from Nasdaq before the special stockholders’ meeting, La Jolla expects that it would need Adamis’ consent and additional regulatory approvals to continue soliciting proxies resulting in significant additional costs and time delays. Such consents and approvals are difficult to obtain and may not be obtained at all.
Holders of more than 50% of La Jolla’s 65 million shares outstanding must vote in order to hold the meeting. For the merger to be completed, holders of more than 50% of La Jolla’s shares must vote in favor. Only stockholders who held La Jolla stock on January 22, 2010 are eligible to vote.
If You Haven’t Received Your Voting Materials – please vote by contacting our proxy vote solicitor, Mackenzie Partners, Inc. as follows:
e-mail at proxy@mackenziepartners.com
call toll free at (800) 322-2885
call collect at (212) 929-5500.
Mackenzie Partners will be able to provide you with voting materials and instructions on how to vote telephonically or through your broker. You may also contact La Jolla by e-mail at gail.sloan@ljpc.com or by telephone at (858) 452-6600.
This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.
Additional Information and Where to Find It
The joint proxy statement/prospectus in connection with the merger with Adamis was mailed to La Jolla stockholders on or about February 12, 2010. Investors and security holders of both La Jolla and Adamis are urged to read the joint proxy statement/prospectus because it contains important information about La Jolla, Adamis and the proposed transaction. The joint proxy statement/prospectus, and any other documents filed by La Jolla with the SEC, may be obtained free of charge at the SEC web site at www.sec.gov, by contacting La Jolla Investor Relations by e-mail at gail.sloan@ljpc.com or by telephone at (858) 452-6600. La Jolla and its respective directors and executive officers may be deemed to be participants in the solicitation of proxies from La Jolla’s stockholders in favor of the proposed transaction. Information about the directors and executive officers of La Jolla and their respective interests in the proposed transaction is available in the joint proxy statement/prospectus.
Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
SAN DIEGO, March 1 /PRNewswire-FirstCall/ --
Anadys Pharmaceuticals, Inc. announced today that it will present at the 30th Annual Cowen and Company Healthcare Conference on Monday, March 8, 2010 at 1:45 p.m. EST (10:45 a.m. PST). The conference is being held at the Boston Marriot Copley Square Hotel. Steve Worland, Ph.D., President and Chief Executive Officer of Anadys, will provide an overview of Anadys and its clinical development programs, ANA598 and ANA773.
The corporate presentation will be simultaneously webcast and can be accessed on the Investor Relations page of the Company's website at http://www.anadyspharma.com/. Listeners are encouraged to visit the website approximately five minutes prior to the corporate presentation to download or install any necessary software. A replay of the presentation will be available approximately one hour after the live webcast concludes and will be available through March 22, 2010.
About Anadys Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C. The Company believes hepatitis C represents a large unmet medical need in which meaningful improvements in treatment outcomes may be attainable with the introduction of new medicines. The Company is developing ANA598, a non-nucleoside polymerase inhibitor for the treatment of hepatitis C. The Company has also investigated the potential of ANA773, an oral, small-molecule inducer of endogenous interferons that acts via the Toll-like receptor 7, or TLR7, pathway in hepatitis C.
Safe Harbor Statement Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Anadys' strategy, development programs, and ability to develop novel medicines for the treatment of hepatitis C. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 or ANA773 will not have unforeseen safety issues, will have favorable results in ongoing or future clinical trials or will receive regulatory approval. Risk factors that may cause actual results to differ are more fully discussed in Anadys' SEC filings, including Anadys' Form 10-K for the year ended December 31, 2009. All forward-looking statements are qualified in their entirety by this cautionary statement. Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. DATASOURCE: Anadys Pharmaceuticals, Inc.
CONTACT: Investors, Amy Conrad of Anadys Pharmaceuticals, Inc.,+1-858-530-3607, aconrad@anadyspharma.com; or Media, Ian Stone,ian.stone@russopartnersllc.com, or David Schull,david.schull@russopartnersllc.com, both of Russo Partners, LLC,+1-619-528-2220, for Anadys Pharmaceuticals, Inc.
Web Site: http://www.anadyspharma.com/
Nice PR. Sometimes these poster presentations may seem insignificant, but occasionally they can bring much needed attention to a stock. Take SNSS for example... Hopefully HRBR is setting up for a move like that.
GL.
APPA rallied into the close... May be setting up to break thru $2 and stay there, IMO.
GLTA.
Heska to Present at LDV Capital Management's Growth and Value Conference
Presentations are Scheduled for March 3rd and 4th
LOVELAND, Colo., March 1 /PRNewswire-FirstCall/ -- Heska Corporation (Nasdaq:HSKA - News) today announced it will present at LDV Capital Management's Growth and Value Conference on March 3rd and 4th, 2010 at the Sheraton Suites Cypress Creek, 555 NW 62nd Street in Fort Lauderdale, FL. The presentation on both days is scheduled to begin at 5:30 p.m. Eastern Time.
About Heska
Heska Corporation (Nasdaq:HSKA - News) sells advanced veterinary diagnostic and other specialty veterinary products. Heska's state-of-the-art offerings to its customers include diagnostic instruments and supplies as well as single use, point-of-care tests, pharmaceuticals and vaccines. The company's core focus is on the canine and feline markets where it strives to provide high value products and unparalleled customer support to veterinarians. For further information on Heska and its products, visit the company's website at www.heska.com.
May close green here, IMO...
GLTA.
HRBR presenting at an ASCO conference on Saturday... May be a good time to pick some up, IMO.
Do your own DD before investing!
GLTA.
Lots of insider purchases recently: http://www.filing4.com/company/symbol/?sym=hska
GLTA.
Picked up some HSKA... Undervalued here, IMO.
GLTA.
Should have news Monday or sometime this week on how the voting went, IMO... Fingers crossed.
GLTA.
Hi $heff,
Any thoughts on INHX?
INHX (Inhibitex, Inc.): www.inhibitex.com
Several forward-looking events coming up:
#1 -
FV-100 for shingles:
The Company anticipates that an interim analysis of the complete 30-day follow-up data on the first half (50%) of patients enrolled in the trial will be completed in the first quarter of 2010. Further, the Company anticipates completing enrollment in and having top-line data available from this trial in the second half of 2010.
#2 -
ROTH CAPITAL PARTNERS TO HOLD 22ND ANNUAL OC GROWTH STOCK CONFERENCE - March 15-17, 2010
http://www.tradingmarkets.com/news/press-release/ensw_geyie_roth-capital-partners-to-hold-22nd-annual-oc-growth-stock-769790.html
Inhibitex is on the list of presenting companies...
Also, insiders are buying, here's a link to form 4 transactions: http://www.nasdaq.com/asp/holdings.asp?symbol=INHX&selected=INHX&FormType=form4
Nice PR... ADMP is positioned for some steady long-term gains, IMO.
GL.
2x the avg. 10day volume today, nice...
BNVI on the move...
Sold SOMX in the low 3.90s and picked up some INHX.
GLTA.
Nice call on it earlier when it was in the 6s!
GL
ROTH CAPITAL PARTNERS TO HOLD 22ND ANNUAL OC GROWTH STOCK CONFERENCE
http://www.tradingmarkets.com/news/press-release/ensw_geyie_roth-capital-partners-to-hold-22nd-annual-oc-growth-stock-769790.html
Inhibitex is on the list of presenting companies...
GLTA.
Inhibitex Provides Update on Its Staph Vaccine, FV-100 and INX-189 Development Programs
Released: 01/11/10 08:00 AM EST
Inhibitex, Inc. (Nasdaq: INHX) today announced that its collaborator, Pfizer, Inc., has initiated patient recruitment for 408-patient, randomized, double-blind Phase I clinical trial to evaluate the safety, tolerability, and immunogenicity of three ascending dose levels of a 3-antigen Staphylococcus aureus (S. aureus) vaccine (SA3Ag) in healthy adults. The SA3Ag vaccine contains an antigen originating from the Company’s MSCRAMM® protein platform. The Company licensed its MSCRAMM® protein platform to Wyeth (acquired by Pfizer in 2009) on an exclusive worldwide basis for the development of active vaccines against staphylococcus in 2001. Pfizer is responsible for all clinical development, manufacturing and marketing of the vaccine. Inhibitex is eligible to receive a payment upon the achievement of this and future regulatory milestones, as well as royalties on future net sales.
In addition to announcing the initiation of this Phase I vaccine study, the Company also provided an update on the status of FV-100, a highly potent oral antiviral compound in Phase II clinical development for the treatment of herpes zoster (shingles), and INX-189, a nucleotide polymerase inhibitor in late preclinical development for the treatment for chronic infections caused by hepatitis C virus (HCV).
FV-100
The independent Data Safety Monitoring Board (DSMB) responsible for reviewing data from the Company’s ongoing Phase II clinical trial of FV-100 met, as scheduled, in early December after the Company had provided it with complete 30-day follow-up data on the first quartile of patients enrolled in the trial. Based upon its review, the DSMB unanimously recommended that the trial should continue, as originally designed, without modification. The Company anticipates that an interim analysis of the complete 30-day follow-up data on the first half (50%) of patients enrolled in the trial will be completed in the first quarter of 2010. Further, the Company anticipates completing enrollment in and having top-line data available from this trial in the second half of 2010.
The Phase II trial is a well-controlled, double-blind study comparing two arms of FV-100 to an active control (valacyclovir). The Company plans to enroll and randomize approximately 350 patients, aged 50 years and older, equally to one of three treatment arms: 200 mg FV-100 administered once daily; 400 mg FV-100 administered once daily; and 1,000 mg valacyclovir administered three times per day. In addition to further evaluating its safety, the objectives of the trial are to evaluate the potential therapeutic benefit of FV-100 in reducing the severity and duration of shingles-related pain, the incidence of post herpetic neuralgia (PHN), and the time to lesion healing.
INX-189
The Company has completed the requisite Good Laboratory Practices (GLP) preclinical studies to support the filing of an investigational new drug application (IND) for INX-189. Based on the results of these studies, the Company continues to anticipate filing an IND and, subject to FDA review, initiating a Phase I clinical trial of INX-189 in the first half of 2010.
About Inhibitex
Inhibitex, Inc., headquartered in Alpharetta, Georgia, is a biopharmaceutical company focused on developing products to treat serious infectious diseases. The Company’s pipeline includes FV-100 for the treatment of shingles and INX-189, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C infections. The Company has additional HCV nucleotide polymerase inhibitors in preclinical development, and has also licensed the use of its proprietary MSCRAMM® protein technology to Pfizer for the development of staphylococcal vaccines.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than historical facts included in this press release, including statements regarding: the anticipated timing of an interim analysis of the 30-day follow-up data from the first half (50%) of the patients enrolled in the FV-100 Phase II trial; the anticipated time to complete enrollment in and having top-line data available from this trial; the anticipated number of patients the Company plans to enroll in this trial; the anticipated time to file an IND and initiate a Phase I clinical trial of INX-189; and the Company’s eligibility to receive future milestone payments and royalties from Pfizer are forward looking statements. These intentions, expectations, or results may not be achieved in the future and various important factors and risks could cause actual results or events to differ materially from the forward-looking statements that the Company makes, including the risk of: either the Company, the FDA, an investigational review board, or a data safety monitoring board (DSMB) suspending or terminating the clinical development of FV-100 for lack of safety, manufacturing issues or other clinical reasons; FV-100 not demonstrating sufficient efficacy in reducing the incidence and severity of shingles-related symptoms, including acute pain and PHN, to be clinically relevant or commercially viable; the clinical sites participating in the FV-100 Phase II trial not being able to recruit a sufficient number of shingles patients to complete the trial in a timely basis; the results of ongoing or future preclinical or clinical studies of INX-189 not supporting its further development; the Company not obtaining regulatory approval on a timely basis, or at all, to advance the development of INX-189 into clinical trials; Pfizer halting the clinical development of its S. aureus vaccine for any reason; obtaining, maintaining and protecting the intellectual property incorporated into and supporting the commercial viability of the Company’s product candidates; maintaining expenses, revenues and other cash expenditures substantially in line with planned or anticipated levels; and Wyeth not terminating or revising its license agreement with the Company. Further information regarding these factors and risks can be found in the Company’s Annual Report on Form 10-K for the year ended December 31, 2008, as filed with the Securities and Exchange Commission, or SEC, on March 23, 2009 and its Quarterly Reports on Form 10-Q for the quarter ended September 30, 2009, as filed with the SEC on November 13, 2009. Given these uncertainties, you should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release.
There may be events in the future that the Company is unable to predict accurately, or over which it has no control. The Company's business, financial condition, results of operations and prospects may change. The Company may not update these forward-looking statements, even though its situation may change in the future, unless it has obligations under the Federal securities laws to update and disclose material developments related to previously disclosed information. The Company qualifies all of the information contained in this press release, and particularly its forward-looking statements, by these cautionary statements.
Inhibitex® and MSCRAMM® are registered trademarks of Inhibitex, Inc.
Contacts:
Inhibitex, Inc.
Russell H. Plumb, Chief Executive Officer
678-746-1136
rplumb@inhibitex.com
or
The Trout Group
Lee Stern, 646-378-2922
lstern@troutgroup.com
Lots of insider buys recently: http://www.mffais.com/inhx
Picked some up today.. Looks good.
GLTA.
Getting closer to the 52wk low here..
GLTA.
Certain Senesco Insiders Purchase Senesco Securities Held by Stanford Venture Capital Holdings
NEW BRUNSWICK, N.J., Feb. 22 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) reported today that certain insiders of Senesco Technologies, Inc., a Delaware corporation, purchased all of the convertible debentures, warrants and common stock of the Company which are held by Stanford Venture Capital Holdings, Inc.
"The closing of this transaction fortifies our shareholder base, and should enable us to more easily attract suitable financing," said Harlan Waksal, M.D., Senesco's Chairman of the Board. "This agreement is also representative of the significant confidence the Board has in the Company's prospects."
About Senesco Technologies, Inc.
Senesco Technologies, Inc. is a U.S. biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer treatments. Delaying apoptosis may have applications to certain inflammatory and ischemic diseases. Senesco takes its name from the scientific term for the aging of plant cells: senescence. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress. The Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene-regulating platform technology to enhance its partners' products.
Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the ability of the Company to consummate additional financings; the development of the Company's gene technology; the approval of the Company's patent applications; the successful implementation of the Company's research and development programs and joint ventures; the success of the Company's license agreements; the successful conversion of the Company's letter of intent into a license agreement; the acceptance by the market of the Company's products; success of the Company's preliminary studies and preclinical research; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Company Contact:
Investor Relations Contact:
Senesco Technologies, Inc.
FD
Jack Van Hulst
Brian Ritchie
Chief Executive Officer
(brian.ritchie@fd.com)
(jvanhulst@senesco.com)
(212) 850-5600
(732) 296-8400